肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗

2020-04-27 加拿大安大略癌症治疗中心 Curr Oncol . 2020 Apr;27(2):e106-e114.

肝细胞癌

本文由加拿大安大略癌症治疗中心(CCO)胃肠部位疾病组制定，主要针对晚期肝细胞癌的非手术治疗提出了5条推荐意见。

中文标题：

2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗

英文标题：

Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline

发布机构：

加拿大安大略癌症治疗中心

发布日期：

2020-04-27

简要介绍：

本文由加拿大安大略癌症治疗中心(CCO)胃肠部位疾病组制定，主要针对晚期肝细胞癌的非手术治疗提出了5条推荐意见。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3610e1c0019163c1, title=2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗, enTitle=Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline, guiderFrom=Curr Oncol . 2020 Apr;27(2):e106-e114., authorId=0, author=, summary=本文由加拿大安大略癌症治疗中心(CCO)胃肠部位疾病组制定，主要针对晚期肝细胞癌的非手术治疗提出了5条推荐意见。, cover=https://img.medsci.cn/2020610/1591802847998_2020535.jpg, journalId=0, articlesId=null, associationId=13, associationName=加拿大安大略癌症治疗中心, associationIntro=加拿大安大略癌症治疗中心（CCO，Cancer Care Ontario）是致力于不断改善癌症服务的省级机构，同时为政府的癌症顾问，主要任务包括指导和监督医院和其他组织提供高质量及时的癌症服务；执行省级的癌症预防和筛查方案；与专业人员和组织一起制定和实施质量改进和标准；推进癌症临床实践的改进和创新等等。, copyright=0, guiderPublishedTime=Mon Apr 27 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本文由加拿大安大略癌症治疗中心(CCO)胃肠部位疾病组制定，主要针对晚期肝细胞癌的非手术治疗提出了5条推荐意见。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=357, guiderKeyword=肝细胞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2726, appHits=111, showAppHits=0, pcHits=477, showPcHits=2615, likes=0, shares=2, comments=7, approvalStatus=1, publishedTime=Wed Jun 10 23:57:00 CST 2020, publishedTimeString=2020-04-27, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 10 23:27:33 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Mon Jan 01 13:03:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗.pdf)])
2020 CCO临床实践指南：晚期肝细胞癌的非手术治疗.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080759, encodeId=71381080e5981, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Thu Dec 16 15:24:10 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948037, encodeId=261894803e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785446569, createdName=ms8000001320216300, createdTime=Sun Mar 14 09:45:07 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946618, encodeId=f41694661842, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/41378976434d42cb9f1a95092d0855fc/1f4092a3f3564d478e682a75953fa59d.jpg, createdBy=4c515225231, createdName=有治青年, createdTime=Mon Mar 08 23:48:15 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906004, encodeId=f25c9060042f, content=好指南，实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 14:47:32 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894280, encodeId=a7b789428055, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e10d2265523, createdName=陆梓文, createdTime=Sun Oct 25 11:45:24 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2021-12-16 ms9000000410256940

    实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080759, encodeId=71381080e5981, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Thu Dec 16 15:24:10 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948037, encodeId=261894803e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785446569, createdName=ms8000001320216300, createdTime=Sun Mar 14 09:45:07 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946618, encodeId=f41694661842, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/41378976434d42cb9f1a95092d0855fc/1f4092a3f3564d478e682a75953fa59d.jpg, createdBy=4c515225231, createdName=有治青年, createdTime=Mon Mar 08 23:48:15 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906004, encodeId=f25c9060042f, content=好指南，实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 14:47:32 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894280, encodeId=a7b789428055, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e10d2265523, createdName=陆梓文, createdTime=Sun Oct 25 11:45:24 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2021-03-14 ms8000001320216300

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080759, encodeId=71381080e5981, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Thu Dec 16 15:24:10 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948037, encodeId=261894803e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785446569, createdName=ms8000001320216300, createdTime=Sun Mar 14 09:45:07 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946618, encodeId=f41694661842, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/41378976434d42cb9f1a95092d0855fc/1f4092a3f3564d478e682a75953fa59d.jpg, createdBy=4c515225231, createdName=有治青年, createdTime=Mon Mar 08 23:48:15 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906004, encodeId=f25c9060042f, content=好指南，实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 14:47:32 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894280, encodeId=a7b789428055, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e10d2265523, createdName=陆梓文, createdTime=Sun Oct 25 11:45:24 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2021-03-08 有治青年

    好东西，感谢！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080759, encodeId=71381080e5981, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Thu Dec 16 15:24:10 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948037, encodeId=261894803e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785446569, createdName=ms8000001320216300, createdTime=Sun Mar 14 09:45:07 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946618, encodeId=f41694661842, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/41378976434d42cb9f1a95092d0855fc/1f4092a3f3564d478e682a75953fa59d.jpg, createdBy=4c515225231, createdName=有治青年, createdTime=Mon Mar 08 23:48:15 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906004, encodeId=f25c9060042f, content=好指南，实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 14:47:32 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894280, encodeId=a7b789428055, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e10d2265523, createdName=陆梓文, createdTime=Sun Oct 25 11:45:24 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2020-12-08 14861974m47(暂无昵称)

    好指南，实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080759, encodeId=71381080e5981, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Thu Dec 16 15:24:10 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948037, encodeId=261894803e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785446569, createdName=ms8000001320216300, createdTime=Sun Mar 14 09:45:07 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946618, encodeId=f41694661842, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/41378976434d42cb9f1a95092d0855fc/1f4092a3f3564d478e682a75953fa59d.jpg, createdBy=4c515225231, createdName=有治青年, createdTime=Mon Mar 08 23:48:15 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906004, encodeId=f25c9060042f, content=好指南，实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 14:47:32 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894280, encodeId=a7b789428055, content=好东西，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e10d2265523, createdName=陆梓文, createdTime=Sun Oct 25 11:45:24 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2020-10-25 陆梓文

    好东西，感谢！

    0

相关指南

肝细胞癌癌前病变的诊断和治疗多学科专家共识（2020版）

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2020-03-15

肝细胞癌微创与多学科综合诊疗——2018 广州共识

亚太影像引导下肿瘤微创治疗协会 · 2019-07-30

中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南

中国医师协会介入医师分会 · 2018-12-30

2018 台湾多学科建议：应用DEBDOX-TACE治疗肝细胞癌

台湾多学科工作组（统称） · 2018-10-07

2018 ESMO临床实践指南：肝细胞癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2018-10-01

《2018年欧洲肝病学会临床实践指南：肝细胞癌的管理》推荐意见

暂未更新 · 2018-06-10

拓展阅读

2013 JSH循证临床实践指南：肝细胞癌-更新版（JSH-HCC指南第3版）

日本肝脏学会(JSH,The Japan Society of Hepatology) · 2015-01-20

肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2016年版）

全国肝癌合并癌栓诊治研究协作组 · 2016-06-02

肝脏影像报告和数据系统管理工作组肝细胞癌诊断共识意见

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2016-06-02

肝细胞癌合并血管侵犯专家共识（讨论稿）

中国医疗保健国际交流促进会 · 2016-06-02

2014年KLCSG-NCC实践指南：肝细胞癌

暂未更新 · 2016-06-03

肝细胞癌合并门静脉癌栓多学科诊治—东方肝胆外科医院专家共识

肝胆外科专家组（统称） · 2016-06-03